A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to
evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical
activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or
without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with
non-squamous Non-Small Cell Lung Cancer (NSCLC).